Literature DB >> 23171831

Glycemic variability is complex--is glucose complexity variable?

Roosmarijn T M van Hooijdonk, Ameen Abu-Hanna, Marcus J Schultz.   

Abstract

Observational studies show an independent association between increased glycemic variability and higher mortality in critically ill patients. Minimization of glycemic variability is therefore suggested as a new target of glycemic control, which may require very frequent or almost continuous monitoring of glucose levels. Brunner and colleagues show the use of real-time subcutaneous continuous glucose monitoring does not decrease glycemic variability. Continuous glucose monitoring, however, may reveal changes in glucose complexity, which may be of interest since both increased and decreased glucose complexity is associated with higher mortality in the critically ill.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23171831      PMCID: PMC3672583          DOI: 10.1186/cc11834

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


In the previous issue of Critical Care Brunner and colleagues report on the results of a post-hoc analysis [1] of two previously published randomized controlled trials evaluating real-time subcutaneous continuous glucose monitoring (CGM) in critically ill patients [2,3]. Their main findings are that glycemic control guided by real-time CGM does not significantly reduce glycemic variability (GV) and that both increased and decreased glucose complexity is significantly associated with ICU survival and with the presence of diabetes. There is an independent association between increased GV and higher mortality in ICU patients [4,5]. GV depends on endogenous factors (for example, severity of illness) but also on exogenous factors (for example, inappropriate glucose measurement intervals and improper insulin adjustments). Minimization of GV is suggested as a new target of glycemic control [6], which may require very frequent or almost continuous monitoring of glucose levels. However, a secondary analysis of the first two Leuven studies shows that strict glycemic control, which includes frequent monitoring of the blood glucose level, does not decrease GV [7]. The present study shows that strict glycemic control using almost continuous monitoring also does not decrease GV [1]. Therefore it is very difficult, if not impossible, to decrease GV. Are the nurses in Brunner and colleagues' ICU already performing strict glycemic control so well that GV simply cannot be further decreased? Notably, the standard deviation - one of the measures of GV used by the present analysis - is already very low in the control group compared with values reported in previous studies. Nurses could also poorly or only sporadically respond to the real- time CGM results with alterations in insulin infusion, thereby losing any potential for real-time CGM to further decrease GV. We should also not forget that the present study uses subcutaneous glucose levels and not blood glucose levels for calculation of indicators of GV. Subcutaneous GV may simply not be the same as blood GV. Finally, we must keep in mind that the sample frequency per se may affect the calculation of indicators of GV. Indeed, indicators of GV may not only truly reflect GV, but may also depend on the number of measurements per time unit used for its calculation [8]. Brunner and colleagues actually confirm this dependency in their analysis of the impact of the method of glucose determination on indicators of GV [1]. Less well known is that loss of glucose complexity is also associated with higher mortality of critically ill patients. Complex biological systems are characterized by a highly complex output, and one of the first symptoms of disease is decomplexification [9,10]. Well-known examples include decreased intrauterine heart rate complexity with fetal stress, and decreased heart rate and temperature complexity with severe infection. Complexity, in contrast to variability, depends on endogenous factors, and not on exogenous factors. Interestingly, progressive loss of glucose complexity is found from health through the metabolic syndrome to type II diabetes [11-14]. The results of the present study are in line with those findings, at least to some extent. They also echo the results from a previous investigation showing that loss of glucose complexity is associated with higher mortality [15]. The finding that increased glucose complexity is also associated with higher mortality, however, is new. Therefore, next to hyperglycemia, hypoglycemia and GV, glucose complexity should be seen as one new domain of glycemia (Figure 1), although glucose complexity cannot be changed by titration of insulin.
Figure 1

Schematic view of the four domains of blood glucose control. [1] hyperglycemia, [2] hypoglycemia, [3] glycemic variability, and [4] glucose complexity. CGM, continuous glucose monitoring.

Schematic view of the four domains of blood glucose control. [1] hyperglycemia, [2] hypoglycemia, [3] glycemic variability, and [4] glucose complexity. CGM, continuous glucose monitoring. As we speak, several CGM systems are being developed and clinically tested in critically ill patients. These systems all have the potential to improve performance and safety of insulin titration in the ICU. They may also improve our insights into insulin resistance and help us to better understand the impact of GV on outcome. The present study not only shows that GV does not improve with the use of CGM per se, but also suggests that we need to develop better measures of GV, independent of the sample frequency. Finally, CGM systems allow us to determine and follow changes in glucose complexity. This allows one to inspect whether glucose complexity increases (from decreased complexity) or decreases (from increased complexity) in individual patients, and to determine whether these changes follow changes in insulin resistance over time. If this indeed is the case, then CGM could even help us in decisions to start or stop strict glycemic control in individual patients, thereby preventing side effects of insulin infusion.

Abbreviations

CGM: continuous glucose monitoring; GV: glycemic variability.

Competing interests

MJS has performed consulting work for Medtronic Inc., GlySyre Ltd, Roche Diagnostics, Edwards Life Sciences, and Optiscan Biomedical, and has received research support from Medtronic Inc. and Optiscan Biomedical. RTMvH has performed consulting work for Medtronic Inc., GlySyre Ltd, and has received research support from Medtronic Inc. and Optiscan Biomedical. AAH declares that he has no competing interests.
  15 in total

1.  Fractal dynamics in physiology: alterations with disease and aging.

Authors:  Ary L Goldberger; Luis A N Amaral; Jeffrey M Hausdorff; Plamen Ch Ivanov; C-K Peng; H Eugene Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

2.  The lack of long-range negative correlations in glucose dynamics is associated with worse glucose control in patients with diabetes mellitus.

Authors:  Hitomi Ogata; Kumpei Tokuyama; Shoichiro Nagasaka; Takeshi Tsuchita; Ikuyo Kusaka; Shun Ishibashi; Hiroaki Suzuki; Nobuhiro Yamada; Kumiko Hamano; Ken Kiyono; Zbigniew R Struzik; Yoshiharu Yamamoto
Journal:  Metabolism       Date:  2012-02-02       Impact factor: 8.694

3.  Blood glucose control in 2010: 110 to 150 mg/dL and minimal variability.

Authors:  Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

4.  Long-range negative correlation of glucose dynamics in humans and its breakdown in diabetes mellitus.

Authors:  Hitomi Ogata; Kumpei Tokuyama; Shoichiro Nagasaka; Akihiko Ando; Ikuyo Kusaka; Naoko Sato; Akiko Goto; Shun Ishibashi; Ken Kiyono; Zbigniew R Struzik; Yoshiharu Yamamoto
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-07-27       Impact factor: 3.619

5.  Detrended fluctuation analysis is considered to be useful as a new indicator for short-term glucose complexity.

Authors:  Naomune Yamamoto; Yutaka Kubo; Kaya Ishizawa; Gwang Kim; Tatsumi Moriya; Toshikazu Yamanouchi; Kuniaki Otsuka
Journal:  Diabetes Technol Ther       Date:  2010-10       Impact factor: 6.118

6.  Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality.

Authors:  Geert Meyfroidt; Daniel M Keenan; Xin Wang; Pieter J Wouters; Johannes D Veldhuis; Greet Van den Berghe
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

7.  Glycemic variability: a strong independent predictor of mortality in critically ill patients.

Authors:  James S Krinsley
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

8.  Glucose variability is associated with intensive care unit mortality.

Authors:  Jeroen Hermanides; Titia M Vriesendorp; Robert J Bosman; Durk F Zandstra; Joost B Hoekstra; J Hans Devries
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

Review 9.  Glucose variability measures and their effect on mortality: a systematic review.

Authors:  Saeid Eslami; Zhila Taherzadeh; Marcus J Schultz; Ameen Abu-Hanna
Journal:  Intensive Care Med       Date:  2011-01-29       Impact factor: 17.440

10.  Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial.

Authors:  Ulrike Holzinger; Joanna Warszawska; Reinhard Kitzberger; Marlene Wewalka; Wolfgang Miehsler; Harald Herkner; Christian Madl
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

View more
  3 in total

1.  Dynamic properties of glucose complexity during the course of critical illness: a pilot study.

Authors:  Emmanuel Godat; Jean-Charles Preiser; Jean-Christophe Aude; Pierre Kalfon
Journal:  J Clin Monit Comput       Date:  2019-03-19       Impact factor: 2.502

Review 2.  Optimal Perioperative Blood Pressure Management.

Authors:  Senthil Packiasabapathy K; Balachundhar Subramaniam
Journal:  Adv Anesth       Date:  2018-09-24

3.  Dynamical glucometry: use of multiscale entropy analysis in diabetes.

Authors:  Madalena D Costa; Teresa Henriques; Medha N Munshi; Alissa R Segal; Ary L Goldberger
Journal:  Chaos       Date:  2014-09       Impact factor: 3.642

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.